ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for

From the ashes of CETP inhibitors emerges obicetrapib, which reduced LDL by 50%, but long-term safety data are still needed.

Related Keywords

Italy , Australia , Monash , South Australia , Milan , Lombardia , Denmark , Kausik Ray , Newamsterdam Pharma , Anne Tybj , Dezima Pharma , Stephen Nicholls , Sanofi Regeneron , Michael Davidson , John Kastelein , Amgen , Pfizer , European Atherosclerosis Society , Md Imperial College London , Dmsc University Of Copenhagen , Phd Monash University , Novartis , Imperial College London , Monash University , Age Related Macular ,